Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -10.81

Evolus, Inc. Price to Earnings Ratio (P/E) is -10.81 on January 14, 2025, a -8.46% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Evolus, Inc. 52-week high Price to Earnings Ratio (P/E) is -9.97 on January 16, 2024, which is 7.80% above the current Price to Earnings Ratio (P/E).
Evolus, Inc. 52-week low Price to Earnings Ratio (P/E) is -20.67 on September 13, 2024, which is -91.19% below the current Price to Earnings Ratio (P/E).
Evolus, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -14.31.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Pharmaceuticals

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years